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Editor
Multicenter bridge to transplantation
with the HeartMate assist device:
Evaluation from another perspective.
A rebuttal
To the Editor:
I appreciate the opportunity to comment on
the editorial by Copeland1 concerning our
article.2 I share Copeland’s concerns about
company-sponsored trials and the possibil-
ity of bias in reports that are not verified by
Food and Drug Administration (FDA)
scrutiny. Company sponsorship always in-
troduces an inherent bias, and the medical
literature is replete with articles addressing
such concerns. I must point out, however,
that all of the data in our report were con-
stantly exposed to third-party critical re-
view by the FDA. Also, as implied in the
article, the data from the multicenter trial
resulted in FDA approval of the device. As
a result, the data we report have the assur-
ance of the accuracy attained by this third-
party critical scrutiny.
Copeland’s criticism of the control
study is inaccurate. The control group was
based on the initial trial for approval of the
pneumatic HeartMate device (Thermo Car-
diosystems, Inc, Woburn, Mass), the first
implantable left ventricular assist device
(LVAD) to be addressed and approved by
the FDA and the only one of the implant-
able devices to go before the scrutiny of a
panel. This control group has also been
referred to by other groups seeking ap-
proval for LVADs. So, our control group
actually represents an important and ac-
cepted group for comparison with patients
with heart failure treated with an LVAD.
The control patients were assigned to treat-
ment, but most could not receive the device
due to its unavailability.
The editorialist’s discussion of the
bleeding complications is unnecessarily
lengthy and confusing, and I am not ex-
actly sure what the point is. All LVADs
continue to have associated bleeding prob-
lems. Such problems, however, improved
markedly in the last part of our study
through the use of aprotinin and other
agents. Moreover, it was not the purpose of
our article to address the details of bleeding
complications associated with the device.
Yet, it is clear that bleeding must be ac-
knowledged as a risk factor in these and all
other high-risk LVAD patients.
Copeland also addresses the biologic
lining of the device. The concern with bi-
ologic linings goes back to the design of
the original implantable devices in the
1960s and was part of the focus of the
development of LVADs sponsored by the
National Heart, Lung, and Blood Institute.
One of the consistent and remarkable find-
ings regarding the HeartMate LVAD’s bi-
ologic lining technology is the low inci-
dence of associated thromboembolic
stroke, even in patients who do not receive
the anticoagulant warfarin sodium (this de-
vice requires aspirin alone). Elsewhere, the
biologic lining has been reported to reduce
platelets, which may contribute to postop-
erative bleeding. I think this would have
been a good topic for comment by Cope-
land.
I take issue with Copeland’s concern
about the adverse events of driveline infec-
tions and device malfunctions. Infection
was not seen in the pneumatic version of
the device but was more of a problem in the
electrical device. It also seemed to be as-
sociated with the proximity of the driveline
exit site to the device. The exit site has
since been changed to more closely mimic
that of the Novacor device (Baxter Health-
care Corp, Novacor Div, Oakland, Calif),
and, with the longer tunnel, the rate of
infection seems to be markedly decreased.
As for device malfunctions, we noted in
our article that 86% of them were malfunc-
tions of external components such as con-
trollers and batteries. No serious complica-
tions occurred in patients as a result of
these events.
I appreciate Copeland’s efforts to put
our work into perspective, but also believe
that several other points would have been
worthy of his comment. First is the fact that
LVADs have been used in more than 4000
patients worldwide and have helped save
otherwise terminally ill patients in about
70% of cases, a point that an editorialist
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could emphasize. Second is the increasing
life-saving role of these devices as access
to transplants decreases. Third is the fact
that all LVADs are still subject to the same
entry criteria that were used in the 1970s
for patients with acute failure-to-wean-
from-bypass. These hemodynamic entry
criteria should be reassessed in view of the
changing medical therapy and the fact that
these implantable pumps are for patients
with chronic heart failure on transplant
waiting lists who experience worsening of
heart failure made manifest primarily by
end-organ failure and not by acute hemo-
dynamic compromise.
O. H. Frazier, MD
Director, Cardiopulmonary Transplantation
Texas Heart Institute
PO Box 20345
Houston, TX 77225-0345
References
1. Copeland J. Multicenter bridge to trans-
plantation with the HeartMate assist de-
vice: Evaluation from another perspec-
tive. J Thorac Cardiovasc Surg. 2003;
125:228-30.
2. Frazier OH, Rose EA, Oz MC, Dembitsky
W, McCarthy P, Radovancevic B, et al.
Multicenter clinical evaluation of the Heart-
Mate vented electric left ventricular assist
system in patients awaiting heart transplan-
tation. J Thorac Cardiovasc Surg. 2001;
122:1186-95.
doi:10.1067/mtc.2003.69
Cerebral protection with retrograde
cerebral perfusion
To the Editor:
In their article Bonser and colleagues1
claim that the cerebral flow resulting from
retrograde cerebral perfusion (RCP) is in-
sufficient to make a major contribution to
cerebral oxygenation and that the brain re-
mains ischemic. In the discussion of their
impressive work, the authors stated cor-
rectly that current data suggest that RCP
might provide only little brain perfusion in
human subjects compared with antegrade
baseline cerebral flow. Should we abandon
this adjunct to hypothermic circulatory ar-
rest, or should we explore methods to max-
imize the benefits from its application? The
effort to improve the effectiveness of RCP
during hypothermic circulatory arrest
should combine reduction of the metabolic
activity with simultaneous increase of
blood flow to fulfill the residual metabolic
requirements of the brain. In a small series
my colleagues and I2 demonstrated that the
introduction of vasodilators and anesthetics
into the retrograde perfusate tripled RCP
flow without increase in pressure and with
concomitant suppression of electric activ-
ity. In the present study it is not stated
whether brain electric activity was moni-
tored, and the individual RCP flow is not
specified. Simple pharmacologic manipula-
tions might augment RCP to 20% or 30%
of cerebral flow instead of only 10%. The
administration of potent anesthetics or
other neuroprotective agents might miti-
gate the metabolic needs of the brain. Such
maneuvers will render the brain less isch-
emic, allowing safer circulatory arrest.
Amir Elami, MD
Department of Cardiothoracic Surgery
Hadassah University Hospital
PO Box 12000
Jerusalem 91120, Israel
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Reply to the Editor:
We thank Elami for his comments concern-
ing our work on retrograde cerebral perfu-
sion (RCP).1 We acknowledged in our dis-
cussion that RCP could contribute to
metabolic support during hypothermic cir-
culatory arrest and that this contribution
could be increased by the use of vasodila-
tors. It is also possible that the use of an-
esthetics or neuroprotective agents during
RCP might afford neuroprotection. The se-
ries quoted by Elami, however, describes
only anecdotal evidence from 3 patients
undergoing differing pharmacologic inter-
ventions.2 This report described no moni-
toring of cerebral metabolism or perfusion,
therefore making inferences regarding ce-
rebral metabolic activity and blood flow
unreliable. We have previously reported
that RCP can provide some brain perfu-
sion, but we have questioned what fraction
of retrograde flow provides true brain per-
fusion.3,4 It is quite possible that increased
flow achieved by means of vasodilator ad-
ministration bypasses the brain through
venovenous and venoarterial collaterals.4
Any assumption that increasing flow in-
creases true brain perfusion and neuropro-
tection requires rigorous enquiry. We
would agree that the jury remains out on
RCP and that a beneficial clinical effect
remains to be proven. Such therapeutic in-
terventions therefore require assessment as
part of randomized controlled trials if their
efficacy is to be completely investigated.
Robert Bonser, FRCP, FRCS
Deborah Harrington, MRCS
Domenico Pagano, MD, FRCS
Department of Cardiothoracic Surgery
Queen Elizabeth Hospital
Edgbaston
Birmingham B15 2TH, United Kingdom
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Angiogenesis by means of
endothelial cell transplantation
To the Editor:
In their article, “Angiogenesis by Endothe-
lial Cell Transplantation,” Kim and asso-
ciates1 present results of a novel and in-
triguing approach to angiogenic therapy.
Their preliminary report that endothelial
cell transplantation into a myocardial
scar accelerates angiogenesis suggests
a promising alternative to angiogenic
gene or protein therapy. About the same
time that their article was published, we2
presented similar results before the Amer-
ican Heart Association at our annual sci-
entific session (Anaheim, Calif) in No-
vember 2001.
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